Abstract
Immunotherapy (IT) and targeted therapies (TT) have improved survival for many patients (pts) with metastatic non-small cell lung cancer (mNSCLC). However, the lived experience of this cohort of pts is under-studied. We conducted a single centre, qualitative study to understand concerns and supportive care needs of this novel survivor population. (Complementary data was accepted for online only abstract at ASCO 2020)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.